Conversation

Notices

1. Ars Technica (arstechnica@mastodon.social)'s status on Thursday, 01-Feb-2024 09:19:13 JST Ars Technica

   Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal

   The move ends a long saga that "ended up doing a lot of actual damage."

   https://arstechnica.com/science/2024/01/biogen-dumps-dubious-alzheimers-drug-after-profit-killing-fda-scandal/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social

   • MegatronicThronBanks (megatronicthronbanks@mastodon.social)'s status on Thursday, 01-Feb-2024 10:22:36 JST MegatronicThronBanks

     in reply to

     @arstechnica PHEW, for a second I thought this was about Lycambe or its new sibling!